– Phase 1 clinical trial designed to assess the safety, pharmacokinetics and preliminary efficacy of VIR-5500 in combination with androgen receptor pathway inhibitors in first-line mCRPC – Clinical ...
Vir Biotechnology has dosed the first subject in the non-randomised Phase I trial to assess VIR-5525, the investigational dual-masked T-cell engager (TCE) that targets epidermal growth factor receptor ...
Investors in Vir Biotechnology Inc (Symbol: VIR) saw new options become available this week, for the April 14th expiration. One of the key inputs that goes into the price an option buyer is willing to ...
On Friday, 15 December, as part of a major tour of iconic world venues, India’s biggest stand-up comedian will perform his hit show MIND FOOL at the Eventim Apollo. This is its UK premiere, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results